Dr. McCollum on Treatment in the First-Line Setting for CRC

Article

A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

A. David McCollum, MD, physician, Texas Oncology, discusses treatment options in the first-line setting for patients with colorectal cancer (CRC).

According to McCollum, there was a burst of activity in the early part of this millennia with the approval of many agents. It was discovered that there were some molecular predictors to optimize regimens for particular forms of CRC.

RAS, BRAF, and HER2 testing might specify certain regimens for patients. Additionally, the sidedness of the tumor may predict which treatment will be successful, explains McCollum.

Related Videos
A panel of 4 experts on colorectal cancer
A panel of 4 experts on colorectal cancer
Judy Hayek, MD, gynecologic oncology fellow, State University of New York (SUNY) Downstate College of Medicine
Leslie M. Randall, MD, MAS, professor, division head, Department of Obstetrics and Gynecology – Gynecologic Oncology, Virginia Commonwealth University School of Medicine Obstetrics and Gynecology
Dimitrios Nasioudis, MD, fellow, Gynecologic Oncology, Perelman School of Medicine, the University of Pennsylvania
Sara Corvigno, MD, PhD, translational researcher, oncology, The University of Texas MD Anderson Cancer Center
I-Chia (Daniel) Liu, MD
Robert W. Mutter, MD
Saad J. Kenderian, MB, CHB, consultant, Division of Hematology, Department of Internal Medicine, Department of Immunology, Department of Molecular Medicine, assistant professor, oncology, immunology, medicine, Mayo Clinic
Mary-Ellen Taplin, MD